Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $756.38, giving the company a market capitalization of 79.49B. It carries a P/E multiple of 18.39 and pays a dividend yield of 45.8%.
On 2026-01-14, Regeneron(REGN) stock moved within a range of $753.82 to $766.64. With shares now at $756.38, the stock is trading +0.3% above its intraday low and -1.3% below the session's peak.
Trading activity shows a volume of 209.17K, compared to an average daily volume of 826.79K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful i...
AbbVie ABBV announced that it has signed an agreement with the Trump administration to lower drug prices in the United States. Under the agreement, AbbVie has...
Advertisement Analyst upgrades and what they might mean for REGN Regeneron Pharmaceuticals (REGN) has come into focus after multiple analysts, including Bank...
Analyst ratings
70%
of 30 ratingsMore REGN News
If you are wondering whether Regeneron Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. This article is built to help...
In recent trading, shares of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $816.30, changing ha...
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment? As investors digest the latest upgrad...
